Adding belzutifan after kidney-cancer surgery delayed relapse, not death

Adding the oral drug belzutifan to pembrolizumab after kidney-cancer surgery lowered the risk of the cancer coming back — but in the phase 3 LITESPARK-022 trial it did not, at least not yet, help patients live longer, and it roughly doubled the rate of serious side effects [s1]. On the strength of the recurrence result, the US Food and Drug Administration approved the belzutifan-plus-pembrolizumab combination on 12 June 2026 for adjuvant treatment of clear-cell renal-cell carcinoma at intermediate-high or high risk of returning after surgery [s2][s3].

The trial tested a specific proposition: that layering a second mechanism onto an already-approved therapy does better than that therapy alone. Pembrolizumab, an immunotherapy, is already standard after surgery for high-risk kidney cancer, where it improves both recurrence and survival [s1]. Belzutifan blocks HIF-2-alpha, a driver of clear-cell kidney tumours, and works in advanced disease [s1]. LITESPARK-022 asked whether the two together beat pembrolizumab plus placebo.

What they did

In this double-blind trial, 921 patients received pembrolizumab (400 mg intravenously every six weeks, up to nine doses) plus daily belzutifan at 120 mg, and 920 received pembrolizumab plus placebo, each for up to one year [s1]. The main outcome was disease-free survival — time until the cancer recurred, spread, or the patient died — as judged by the treating investigators; overall survival was a secondary outcome [s1].

What it showed

At a median follow-up of 28.4 months, disease-free survival was significantly better with the combination: the hazard ratio for recurrence or death was 0.72 (95% confidence interval, 0.59 to 0.87; P<0.001) [s1]. In plain terms, adding belzutifan cut the risk of recurrence or death by 28% over the follow-up period. The estimated share of patients still disease-free at 24 months was 80.7% with the combination and 73.7% with pembrolizumab alone [s1].

Survival is where the story turns cautious. At this interim analysis — with only 29% of the deaths needed for the final survival readout — overall survival did not differ significantly between the groups (hazard ratio for death, 0.78; 95% confidence interval, 0.51 to 1.19; P=0.24) [s1]. Estimated 24-month overall survival was 96.2% with the combination and 95.7% without it [s1]. The FDA label records the same immaturity: at approval, the survival data were not mature [s2].

The cost side of the ledger

The added benefit came with added harm. Grade 3 or higher adverse events — the serious end of the scale — occurred in 52.1% of patients on the combination versus 30.2% on pembrolizumab alone [s1]. Belzutifan's label carries warnings for anemia and for hypoxia, low blood-oxygen levels that can require oxygen or hospitalisation [s2]. So the trade being offered is concrete: a meaningful reduction in early recurrence, paid for with a substantially higher chance of a serious side effect, and without — so far — evidence that it lengthens life.

Why the survival gap matters here

Disease-free survival is a surrogate: it counts relapses, not deaths, on the reasonable assumption that preventing relapse prevents death. In adjuvant kidney cancer that assumption has a mixed history, which is why the immature survival curve is not a footnote but the crux. A recurrence delayed is worth something on its own — fewer scans that bring bad news, more time before the next line of treatment — but it is not the same as a life extended, and the honest reading of LITESPARK-022 today is that it has shown the first and not the second. The same distinction runs through other adjuvant immunotherapy trials, where a delay in recurrence and an extension of life have not always arrived together, and through cancer drugs cleared on interim endpoints generally.

For patients weighing the option, the numbers to hold in mind are these: a 28% lower risk of recurrence, no proven survival benefit yet, and serious side effects in about half of those treated [s1]. The final survival analysis will decide whether the recurrence benefit was worth it.

Sources

• [s1] Choueiri TK, Motzer RJ, Karam JA, et al. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (LITESPARK-022). New England Journal of Medicine. 1 July 2026.
• [s2] U.S. Food and Drug Administration. Welireg (belzutifan) tablets — Prescribing Information. 12 June 2026.
• [s3] U.S. Food and Drug Administration. NDA 215383/S-015 Supplement Approval Letter — Welireg (belzutifan) tablets. 12 June 2026.